Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

Temozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to 1000 mg m-2 over 5 days (i.e. 200 mg m-2 day-1) if no significant myelosuppression was noted at day...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Woll, P. J., Crowther, D., Johnson, P. W., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., Newlands, E. S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 1995
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2034149/
https://ncbi.nlm.nih.gov/pubmed/7599050
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi